ENVX: Held by 1 Biotech Hedge Fund (2026) | BiotechEdge

Catalysts Convergence Squeeze SignalsNEW Cash Runway Insiders M&A Research

Home›Companies›Enovix Corp (ENVX)

Enovix Corp

ENVX

Held by 1 specialist biotech fund

1 fund opened new positions. Short interest: 27.2% of float.

Electrical Equipment & PartsCEO: Raj TalluriIPO: 2021Website ↗

Enovix Corporation designs, develops, and manufactures lithium-ion batteries. The company was founded in 2007 and is headquartered in Fremont, California.

Score Holdings Short Interest Catalysts Insiders Research

BiotechEdge

Catalysts Conferences Companies Convergence Fund Insiders Signals Squeeze Cash Runway Research Weekly Briefs 13F Changes Glossary PricingSign In Start 14-Day Free Trial

Data sourced from SEC EDGAR and ClinicalTrials.gov. Not investment advice.

Feedback

Signal Score

3.5/10

1 fund opened new positions●●

No recent insider activity●●

No upcoming catalysts●●

Held by 1 specialist fund●●

See how each signal contributes— fund overlap, insider activity, catalyst timing, short interest (free trial)

Fund Holdings

Driehaus Capital

Position history (shares)

Driehaus Capital

AI Signal

SIGNAL NOTE: ENOVIX (ENVX)

Growth-focused Driehaus initiating a $39.9M position signals conviction in ENVX's solid-state battery technology for EVs, though the signal carries moderate weight as a single large-cap growth fund entry. Key near-term catalysts include ramp of commercial production at their Delaware facility and automotive OEM adoption timelines; however, ENVX faces execution risk on manufacturing scale and competitive pressure from established battery makers.

Unlock full AI analysis — 14-day free trial

6 quarters

Position Trend

May 15, 2025

$17.1M

1 fund

Aug 14, 2025

$6.6M

1 fund

Nov 14, 2025

$8.0M

1 fund

Feb 17, 2026

0 funds

-100% total institutional value over 11 quarters

Short Interest

SI declining 3 periods (-10.1%)

Short Shares

52.93M

Change

-4.0%

Days to Cover

9.3

% of Float

27.2%

Settlement

Apr 30, 2026

Short interest over 6 periods

Catalysts

No catalysts tracked.

Be first to know when this name moves

Fund buys and exits, insider activity, and catalyst alerts across 800+ biotechs — free Monday brief.

Position Details

Driehaus CapitalEXITFeb 17, 2026

Start free trialfor share counts, dollar values & AI analysis

10 more position changes — start your free trial to see dollar values and AI analysis for all of them.

Know which insider moves are real

See who's buying with their own money vs. routine exercises
AI explains why each move matters right now

Start 14-Day Free Trial — $29/mo

Insider Signals

No insider purchases or sales detected in the past 90 days.

Also Held by These Funds

LRCX1 fund LRMR1 fund SWIM1 fund TVTX1 fund TARS1 fund TER1 fund GHM1 fund AGYS1 fund

Research Links

Yahoo Finance →SEC EDGAR →ClinicalTrials.gov →

Related Research

Verdad's Biotech White Paper, Part 1: Why Specialist Fund Holdings Predict Returns

6 min read

Verdad's Biotech White Paper, Part 2: Why Traditional Quant Factors Fail — and What Works Instead

6 min read

Fund Convergence: The Highest-Conviction Signal in Biotech Investing

5 min read

Track specialist biotech funds, insider signals, and AI analysis

Start 14-Day Free Trial

Get free weekly alerts on fund moves and catalysts:

Terms

Privacy

Disclaimer